Status:

COMPLETED

Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

Lead Sponsor:

Eli Lilly and Company

Conditions:

Non-small Cell Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and...

Eligibility Criteria

Inclusion

  • histologic or cytologic proof of single primary non-small cell lung cancer
  • No prior chemotherapy or radiation therapy
  • no prior malignancy

Exclusion

  • pregnancy or breastfeeding
  • serious concomitant systemic disorder
  • unintentional weight loss greater than 10%

Key Trial Info

Start Date :

March 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2009

Estimated Enrollment :

64 Patients enrolled

Trial Details

Trial ID

NCT00191139

Start Date

March 1 2003

End Date

February 1 2009

Last Update

February 17 2010

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph

Denver, Colorado, United States, 80218

2

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph

South Bend, Indiana, United States, 46601

3

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph

Baltimore, Maryland, United States, 21237

4

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph

Kalamazoo, Michigan, United States, 49048